Therapeutic manipulation of myosin can abate the effects of MYBPC3 mutations in hypertrophic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Should not change HCM practice; leaves open myosin modulation for MYBPC3 mutations pending human trials.
Mutations in MYBPC3 disrupt myosin states of relaxation, and manipulating myosin therapeutically abates the effects of MYBPC3 mutations.
No takes yet. Share an insight, caveat, or question.
Toepfer et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: